207_Combined course Presentations

Toxicity of concurrent SRT and immune checkpoint inhibition Anti-CTLA-4 (ipilimumab)  Concurrent cranial SRT with ipilimumab is safe.

 Limited data on the use ipilimumab concurrent with extra-cranial SRT.

Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37